A Review of Clinical Studies and Practical Guide for the Administration of Triplet Chemotherapy Regimens with Bevacizumab in First-line Metastatic Colorectal Cancer

dc.contributor.authorLoupakis, Fotios
dc.contributor.authorStein, Alexander
dc.contributor.authorYchou, Marc
dc.contributor.authorHermann, Frank
dc.contributor.authorSalud Salvia, Maria Antonieta
dc.contributor.authorÖsterlund, Pia
dc.date.accessioned2021-03-24T11:15:37Z
dc.date.available2021-03-24T11:15:37Z
dc.date.issued2016
dc.description.abstractColorectal cancer is the third most common cancer worldwide. A significant proportion of patients presents with unresectable metastatic disease or develops metachronous metastases following surgical resection of the primary tumor. The prognosis of the disease has improved over the past two decades, with extended multimodality treatment options and the development of increasingly intensified chemotherapy regimens that now typically include targeted biologics. A recent advance in therapy is a treatment regimen composed of three chemotherapeutic agents (i.e., triplet chemotherapy: 5-fluorouracil [5-FU]/leucovorin [LV], oxaliplatin, and irinotecan; FOLFOXIRI) in combination with the vascular endothelial growth factor inhibitor bevacizumab. This regimen has been shown to elicit significantly improved objective response rates and median progression-free survival compared with 5-FU/LV and irinotecan in combination with bevacizumab. However, triplet chemotherapy has been associated with increased rates of chemotherapy-related adverse events, and treatment-emergent adverse events should be properly managed to minimize treatment interruption or discontinuation. We present herein a review of clinical studies evaluating the safety and efficacy of FOLFOXIRI with bevacizumab in metastatic colorectal cancer, and propose a practical guide for the management of adverse events associated with the regimen.ca_ES
dc.description.sponsorshipSupport for third-party medical writing assistance was provided by Genentech, Inc.ca_ES
dc.identifier.doihttps://doi.org/10.1007/s11523-015-0400-y
dc.identifier.issn1776-260X
dc.identifier.urihttp://hdl.handle.net/10459.1/70884
dc.language.isoengca_ES
dc.publisherSpringerca_ES
dc.relation.isformatofReproducció del document publicat a https://doi.org/10.1007/s11523-015-0400-yca_ES
dc.relation.ispartofTargeted Oncology, 2016, vol. 11, núm. 3, p. 293-308ca_ES
dc.rightscc-by-nc (c) Loupakis et al., 2016ca_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccessca_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/*
dc.subject.otherCòlon -- Càncerca_ES
dc.subject.otherQuimioteràpiaca_ES
dc.subject.otherAnticossos monoclonalsca_ES
dc.titleA Review of Clinical Studies and Practical Guide for the Administration of Triplet Chemotherapy Regimens with Bevacizumab in First-line Metastatic Colorectal Cancerca_ES
dc.typeinfo:eu-repo/semantics/articleca_ES
dc.type.versioninfo:eu-repo/semantics/publishedVersionca_ES
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
taronc_a2016v11n3p293.pdf
Size:
849.13 KB
Format:
Adobe Portable Document Format
Description:
License bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: